Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.

BACKGROUND BRAF V600E is the genetic lesion underlying hairy-cell leukemia. We assessed the safety and activity of the oral BRAF inhibitor vemurafenib in patients with hairy-cell leukemia that had relapsed after treatment with a purine analogue or who had disease that was refractory to purine analogues. METHODS We conducted two phase 2, single-group, multicenter studies of vemurafenib (at a dose of 960 mg twice daily)--one in Italy and one in the United States. The therapy was administered for a median of 16 weeks in the Italian study and 18 weeks in the U.S. study. Primary end points were the complete response rate (in the Italian trial) and the overall response rate (in the U.S. trial). Enrollment was completed (28 patients) in the Italian trial in April 2013 and is still open (26 of 36 planned patients) in the U.S. trial. RESULTS The overall response rates were 96% (25 of 26 patients who could be evaluated) after a median of 8 weeks in the Italian study and 100% (24 of 24) after a median of 12 weeks in the U.S. study. The rates of complete response were 35% (9 of 26 patients) and 42% (10 of 24) in the two trials, respectively. In the Italian trial, after a median follow-up of 23 months, the median relapse-free survival was 19 months among patients with a complete response and 6 months among those with a partial response; the median treatment-free survival was 25 months and 18 months, respectively. In the U.S. trial, at 1 year, the progression-free survival rate was 73% and the overall survival rate was 91%. Drug-related adverse events were usually of grade 1 or 2, and the events most frequently leading to dose reductions were rash and arthralgia or arthritis. Secondary cutaneous tumors (treated with simple excision) developed in 7 of 50 patients. The frequent persistence of phosphorylated ERK-positive leukemic cells in bone marrow at the end of treatment suggests bypass reactivation of MEK and ERK as a resistance mechanism. CONCLUSIONS A short oral course of vemurafenib was highly effective in patients with relapsed or refractory hairy-cell leukemia. (Funded by the Associazione Italiana per la Ricerca sul Cancro and others; EudraCT number, 2011-005487-13; ClinicalTrials.gov number NCT01711632.).

[1]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[2]  B. Falini,et al.  BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. , 2015, Blood.

[3]  M. Berger,et al.  Hematopoietic Stem Cell Origin of BRAFV600E Mutations in Hairy Cell Leukemia , 2014, Science Translational Medicine.

[4]  G. Verhoef,et al.  Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib , 2014, Annals of Hematology.

[5]  M. Holderfield,et al.  Mechanism and consequences of RAF kinase activation by small-molecule inhibitors , 2014, British Journal of Cancer.

[6]  Donavan T. Cheng,et al.  Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. , 2014, Cancer discovery.

[7]  I. Schmidt-Wolf,et al.  Hairy cell leukemia: short review, today's recommendations and outlook , 2014, Blood Cancer Journal.

[8]  A. Saven,et al.  Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. , 2014, Blood.

[9]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[10]  V. Sondak,et al.  Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma , 2013, Nature Reviews Clinical Oncology.

[11]  E. Hsi,et al.  Phospho-ERKTHR202/Tyr214 Is Overexpressed in Hairy Cell Leukemia and Is a Useful Diagnostic Marker in Bone Marrow Trephine Sections , 2013, The American journal of surgical pathology.

[12]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[13]  B. Falini,et al.  Constant Activation of the RAF-MEK-ERK Pathway As a Diagnostic and Therapeutic Target in Hairy Cell Leukemia. , 2012 .

[14]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[15]  Patrick T. Walsh,et al.  Soluble IL-2Rα (sCD25) Exacerbates Autoimmunity and Enhances the Development of Th17 Responses in Mice , 2012, PloS one.

[16]  P. Hirth,et al.  Vemurafenib: the first drug approved for BRAF-mutant cancer , 2012, Nature Reviews Drug Discovery.

[17]  K. Basso,et al.  A microRNA signature specific for hairy cell leukemia and associated with modulation of the MAPK–JNK pathways , 2012, Leukemia.

[18]  C. von Kalle,et al.  BRAF inhibition in refractory hairy-cell leukemia. , 2012, The New England journal of medicine.

[19]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..

[20]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[21]  K. Flaherty,et al.  RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. , 2012, The New England journal of medicine.

[22]  R. Foà,et al.  Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. , 2012, Blood.

[23]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[24]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[25]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[26]  M. Grever.  How I treat hairy cell leukemia. , 2010, Blood.

[27]  A. Rohatiner,et al.  Long‐term follow‐up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis , 2009, British journal of haematology.

[28]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[29]  H. Kantarjian,et al.  Eradication of minimal residual disease in hairy cell leukemia. , 2006, Blood.

[30]  M. Piris,et al.  Evolving concepts in the pathogenesis of hairy-cell leukaemia , 2006, Nature Reviews Cancer.

[31]  Katia Basso,et al.  Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1) , 2004, The Lancet.

[32]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[33]  K. Basso,et al.  Gene Expression Profiling of Hairy Cell Leukemia Reveals a Phenotype Related to Memory B Cells with Altered Expression of Chemokine and Adhesion Receptors , 2004, The Journal of experimental medicine.

[34]  J. Cawley,et al.  Regulation of hairy-cell survival through constitutive activation of mitogen-activated protein kinase pathways , 2003, Oncogene.

[35]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[36]  C. Dinarello,et al.  Correlation of serum levels of interleukin-1 family members with disease activity and response to treatment in hairy cell leukemia. , 1998, European cytokine network.

[37]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[38]  Jeffrey W. Clark,et al.  Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia , 1988 .

[39]  J. Vardiman,et al.  Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. , 1983, Blood.

[40]  M. Grever,et al.  Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[41]  T. Eberlein,et al.  Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .

[42]  A. Tefferi,et al.  BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.

[43]  J. Stockman,et al.  Distinct Sets of Genetic Alterations in Melanoma , 2007 .

[44]  D. Catovsky,et al.  The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. , 1994, Leukemia & lymphoma.

[45]  D. Longo,et al.  Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. , 1988, Blood.

[46]  H. Pralle,et al.  [Hairy cell leukemia]. , 1976, Hamatologie und Bluttransfusion.